Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Pranlukast. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYSLTR1 known ✓ | Q9Y271 | 17/20 | 0.76 |
| ▸ | CYSLTR2 | Q9NS75 | 17/20 | 0.76 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.75 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.75 |
| ▸ | PGR | P06401 | 1/20 | 0.75 |
| ▸ | HTR1A | P08908 | 1/20 | 0.75 |
| ▸ | AR | P10275 | 1/20 | 0.75 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.75 |
| ▸ | DRD1 | P21728 | 1/20 | 0.75 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.75 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.75 |
| ▸ | PDE4A | P27815 | 1/20 | 0.75 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.75 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.75 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.75 |
| ▸ | DRD3 | P35462 | 1/20 | 0.75 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.75 |
| ▸ | GPR17 | Q13304 | 1/20 | 0.75 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.75 |
| ▸ | RUVBL1 | Q9Y265 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pranlukast SCHEMBL100963 | 1.00 | CYSLTR2 (0.76) | CYSLTR2CYSLTR1ABCC4ABCB11PGR | |
| Pranlukast SCHEMBL31756724 | 0.99 | CYSLTR2 (0.76) | CYSLTR2CYSLTR1ABCC4ABCB11PGR | |
| Pranlukast SCHEMBL3693 | 0.99 | CYSLTR2 (0.76) | CYSLTR2CYSLTR1ABCC4ABCB11PGR | |
| Pranlukast SCHEMBL15546550 | 0.98 | CYSLTR2 (0.75) | CYSLTR2CYSLTR1ABCC4ABCB11PGR | |
| SCHEMBL6960848 | 0.98 | CYSLTR2 (0.75) | CYSLTR2CYSLTR1ABCC4ABCB11PGR | |
| SCHEMBL8163711 | 0.97 | CYSLTR2 (0.76) | CYSLTR2CYSLTR1ABCC4ABCB11PGR | |
| Pranlukast SCHEMBL29227539 | 0.95 | CYSLTR2 (0.71) | CYSLTR2CYSLTR1ABCC4ABCB11PGR | |
| SCHEMBL8149103 | 0.91 | CYSLTR2 (0.64) | CYSLTR2CYSLTR1ABCC4ABCB11PGR | |
| SCHEMBL7474226 | 0.90 | CYSLTR2 (0.63) | CYSLTR2CYSLTR1ABCC4ABCB11PGR | |
| Pranlukast SCHEMBL19816814 | 0.90 | CYSLTR2 (0.64) | CYSLTR2CYSLTR1ABCC4ABCB11PGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7252835-B2 | Agent for preventing and/or treating sinusitis | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-08-07 | — | — | US | claimed |
| US-20050182115-A1 | Agent for preventing and/or treating sinusitis | ONO PHARMACEUTICAL CO., LTD. | 2005-08-18 | — | — | US | claimed |
| US-20030077322-A1 | Solid dispersion system of pranlukast with improved dissolution and method for preparing the same | PEGSPHERE CO., LTD. (KR) | 2003-04-24 | — | — | US | claimed |
| WO-2025018777-A1 | METHOD FOR PREPARING PHARMACEUTICAL COMPOSITION CONTAINING PRANLUKAST AND PHARMACEUTICAL COMPOSITION PREPARED THEREBY | 삼아제약 주식회사 | 2025-01-23 | — | — | WO | disclosed |
| US-20220105082-A1 | NEW FORMULATIONS CONTAINING LEUKOTRIENE RECEPTOR ANTAGONISTS | ENLITISA (SHANGHAI) PHARMACEUTICAL CO., LTD (CN) | 2022-04-07 | — | — | US | disclosed |
| EP-3908284-A1 | NEW FORMULATIONS CONTAINING LEUKOTRIENE RECEPTOR ANTAGONISTS | Jiangyin Mucocare Pharmaceutical Co., Ltd (CN) | 2021-11-17 | — | — | EP | disclosed |
| CN-113613657-A | Novel formulations containing leukotriene receptor antagonists | 江阴优培尔康药业有限公司 | 2021-11-05 | — | — | CN | disclosed |
| WO-2020143744-A1 | NEW FORMULATIONS CONTAINING LEUKOTRIENE RECEPTOR ANTAGONISTS | JIANGYIN MUCOCARE PHARMACEUTICAL CO., LTD. (CN) | 2020-07-16 | — | — | WO | disclosed |
| EP-3305282-A2 | COMPOSITION OF PRANLUKAST-CONTAINING SOLID PREPARATION WITH IMPROVED BIOAVAILABILITY AND METHOD FOR PREPARING SAME | Sama Pharm Co., Ltd. (KR) | 2018-04-11 | — | — | EP | disclosed |
| US-20090317476-A1 | COMBINATION OF DEHYDROEPIANDROSTERONE OR DEHYDROEPIANDROSTERONE-SULFATE WITH A LEUKOTRIENE RECEPTOR ANTAGONIST FOR TREATMENT OF ASTHMA OR CHRONIC OBSTRUCTIVE PULMONARY DISEASE | EPIGENESIS PHARMACEUTICALS, LLC | 2009-12-24 | — | — | US | disclosed |
| EP-1283725-B1 | SOLID DISPERSION SYSTEM OF PRANLUKAST WITH IMPROVED DISSOLUTION, AND THE PREPARING METHOD THEREOF | PEGSPHERE CO LTD (KR) | 2006-07-19 | — | — | EP | disclosed |
| US-20030077322-A1 | Solid dispersion system of pranlukast with improved dissolution and method for preparing the same | PEGSPHERE CO., LTD. (KR) | 2003-04-24 | — | — | US | disclosed |
| EP-0670835-B1 | PROCESS FOR PREPARING BENZOPYRAN COMPOUNDS | SMITHKLINE BEECHAM PLC (GB) | 2003-03-12 | — | — | EP | disclosed |
| EP-0920427-B1 | PROCESS FOR THE PREPARATION OF BENZOPYRAN COMPOUNDS | SMITHKLINE BEECHAM PLC (GB) | 2002-11-20 | — | — | EP | disclosed |
| US-6309674-B1 | ADMINISTERING SMILAX CHINA, OR SIMILIAR PLANT EXTRACT | MEDION RESEARCH LABORATORIES (JP) | 2001-10-30 | — | — | US | disclosed |
| US-6048983-A | Process for the preparation of benzopyran compounds | SMITHKLINE BEECHAM PL.C (GB) | 2000-04-11 | — | — | US | disclosed |
| US-5616721-A | Process for preparing benzopyran compounds | SMITHKLINE BEECHAM PLC (GB) | 1997-04-01 | — | — | US | disclosed |
| US-5596103-A | Process for preparing benzopyran compounds | SMITHKLINE BEECHAM PLC (GB) | 1997-01-21 | — | — | US | disclosed |
| US-5587483-A | Process for preparing tetrazol-5-yl substituted benzopyran compounds | SMITHKLINE BEECHAM PLC (GB) | 1996-12-24 | — | — | US | disclosed |
| WO-1994012492-A1 | PROCESS FOR PREPARING BENZOPYRAN COMPOUNDS | SMITHKLINE BEECHAM PLC (GB) | 1994-06-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220105082-A1 | NEW FORMULATIONS CONTAINING LEUKOTRIENE RECEPTOR ANTAGONISTS | LTB4R, LTB4R2, CYSLTR1 | CYSLTR1 3/4885CYSLTR2 5/4885ABCC4 3473/4885 |
| US-20050182115-A1 | Agent for preventing and/or treating sinusitis | HRH2, PRSS1, PRSS8 | CYSLTR1 143/4885CYSLTR2 187/4885ABCC4 1907/4885 |
| US-20090317476-A1 | COMBINATION OF DEHYDROEPIANDROSTERONE OR DEHYDROEPIANDROSTERONE-SULFATE WITH A LEUKOTRIENE RECEPTOR ANTAGONIST FOR TREATMENT OF ASTHMA OR CHRONIC OBSTRUCTIVE PULMONARY DISEASE | LTB4R, LTB4R2, CYSLTR1 | CYSLTR1 3/4885CYSLTR2 4/4885ABCC4 2224/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.